You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 12, 2025

Drug Price Trends for ZOLPIDEM TART


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for ZOLPIDEM TART

Average Pharmacy Cost for ZOLPIDEM TART

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
ZOLPIDEM TART ER 12.5 MG TAB 00955-1703-10 0.10873 EACH 2025-01-22
ZOLPIDEM TART 1.75 MG TAB SL 49884-0898-11 4.81312 EACH 2025-01-22
ZOLPIDEM TART 3.5 MG TABLET SL 49884-0899-52 5.71205 EACH 2025-01-22
ZOLPIDEM TARTRATE 7.5 MG CAP 52427-0775-30 7.98462 EACH 2025-01-22
ZOLPIDEM TART ER 12.5 MG TAB 47335-0308-88 0.10873 EACH 2025-01-22
ZOLPIDEM TART 1.75 MG TAB SL 49884-0898-52 4.81312 EACH 2025-01-22
ZOLPIDEM TART ER 12.5 MG TAB 10370-0116-10 0.10873 EACH 2025-01-22
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for ZOLPIDEM TART

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
ZOLPIDEM TARTRATE 5MG TAB AvKare, LLC 42291-0963-30 30 3.39 0.11300 EACH 2023-06-15 - 2028-06-14 FSS
ZOLPIDEM TARTRATE 10MG TAB AvKare, LLC 42291-0964-01 100 3.70 0.03700 EACH 2024-01-12 - 2028-06-14 FSS
ZOLPIDEM TARTRATE 10MG TAB AvKare, LLC 42291-0964-10 1000 36.55 0.03655 EACH 2024-01-12 - 2028-06-14 FSS
ZOLPIDEM TARTRATE 10MG TAB AvKare, LLC 42291-0964-30 30 3.29 0.10967 EACH 2023-06-15 - 2028-06-14 FSS
ZOLPIDEM TARTRATE 6.25MG TAB,SA Golden State Medical Supply, Inc. 51407-0554-01 100 19.10 0.19100 EACH 2023-06-15 - 2028-06-14 FSS
ZOLPIDEM TARTRATE 5MG TAB AvKare, LLC 42291-0963-01 100 3.80 0.03800 EACH 2024-01-12 - 2028-06-14 FSS
ZOLPIDEM TARTRATE 12.5MG TAB,SA Golden State Medical Supply, Inc. 51407-0555-01 100 19.10 0.19100 EACH 2023-06-15 - 2028-06-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Zolpidem Tartrate Market Analysis and Price Projections

Market Overview

The zolpidem tartrate market is a significant segment within the pharmaceutical industry, primarily catering to the treatment of insomnia and other sleep-related disorders. Here are the key points that define the current and future landscape of this market.

Market Size and Growth Projections

  • The global zolpidem tartrate market was valued at approximately USD 1 billion in 2023 and is expected to reach USD 9.58 billion by 2031, growing at a CAGR of 8.2% from 2024 to 2031[1].
  • Another projection indicates that the market could reach USD 968.6 million by 2031, expanding at a CAGR of 3.2% during the forecast period[3].
  • The zolpidem tartrate tablets market specifically was valued at around USD 2.8 billion in 2023 and is projected to reach over USD 3.5 billion by 2033, with a CAGR of around 5% from 2024 to 2033[5].

Drivers of Market Growth

Increasing Prevalence of Insomnia

The rising incidence of insomnia and other sleep disorders globally is a major driver of the zolpidem tartrate market. Approximately 30% of the general population suffers from insomnia, with higher prevalence rates observed in older adults and women[3].

Aging Population

The aging population is another significant factor. As the number of people aged 60 years and above is projected to more than double by 2050, the demand for zolpidem tartrate is expected to increase substantially[3].

Advances in Pharmaceutical Formulations

Improvements in patient compliance and efficacy brought about by extended-release and sublingual tablet formulations are driving market growth. These advancements have made zolpidem tartrate more appealing as a treatment option[1][5].

Growing Awareness and Healthcare Infrastructure

Rising awareness of mental health and the growing healthcare infrastructure, particularly in regions like North America and Europe, are contributing to the market's expansion. High healthcare expenditures in these regions have facilitated the adoption of advanced treatments for sleep disorders[1][3][5].

Regional Analysis

North America

North America, particularly the United States, is the largest market for zolpidem tartrate tablets. The high prevalence of sleep disorders, well-established healthcare infrastructure, and the presence of major pharmaceutical companies are key drivers of this market[5].

Europe

Europe is also expected to grow rapidly due to the increasing prevalence of insomnia and sleep disorders. Approximately 40% of the European population suffers from sleep disorders, making this region a significant market opportunity[3].

Asia-Pacific, Latin America, and Middle East & Africa

These regions present significant growth opportunities due to the rising prevalence of sleep disorders and increasing healthcare investments. However, they may face challenges related to infrastructure, access to healthcare, and regulatory complexities[5].

Market Segmentation

By Product Type

The market is segmented into immediate-release tablets and extended-release tablets. The introduction of generics and advanced formulations such as sublingual and extended-release variants has expanded treatment options for patients[5].

By Distribution Channel

The market is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. The convenience and accessibility offered by online pharmacies are expected to contribute to market growth[5].

Price Projections and Cost Analysis

Cost Without Insurance

Without insurance, a 30-day supply of generic zolpidem tartrate costs approximately $90, which translates to about $3 per tablet for the highest dose of 10 mg tablets[4].

Comparative Pricing

Zolpidem tartrate is generally more cost-effective compared to other sleep aids. For example, generic zaleplon and eszopiclone have higher retail prices than zolpidem tartrate[4].

Market Dynamics and Challenges

Drivers

  • Increasing prevalence of insomnia and sleep disorders.
  • Growing awareness and acceptance of nonbenzodiazepine sedative-hypnotics.
  • Advances in pharmaceutical formulations.
  • Expanding healthcare infrastructure and rising healthcare spending[1][3][5].

Restraints

  • Regulatory measures and concerns over dependency.
  • Potential side effects and the need for careful prescribing practices.
  • Competition from other sleep aids and generic alternatives[5].

Impact of COVID-19

The COVID-19 pandemic has positively impacted the zolpidem tartrate market. Increased stress, anxiety, and disrupted sleep patterns due to lockdowns and other restrictions have led to a surge in demand for sleep aids, including zolpidem tartrate[3].

Key Players

Major manufacturers in the zolpidem tartrate market include Sanofi, Merit Pharmaceutical, Par Pharmaceutical, Teva Pharmaceuticals USA, Inc., and Astellas Pharma US, Inc.[3].

Future Outlook

The zolpidem tartrate market is expected to experience sustained growth driven by the rising prevalence of insomnia, increasing awareness of sleep disorders, and innovations in formulation and delivery methods. Regulatory measures and dependency concerns may pose challenges, but the market is poised for continued development with a focus on safety, efficacy, and patient compliance[5].

Key Takeaways

  • The zolpidem tartrate market is projected to grow significantly due to the increasing prevalence of insomnia and other sleep disorders.
  • Advances in pharmaceutical formulations and growing healthcare infrastructure are key drivers.
  • North America and Europe are the largest markets, but emerging regions offer significant growth opportunities.
  • The market faces challenges such as regulatory measures and dependency concerns but is expected to grow with a focus on safety and efficacy.

FAQs

What is the projected market size of zolpidem tartrate by 2031?

The global zolpidem tartrate market is expected to reach USD 9.58 billion by 2031, growing at a CAGR of 8.2% from 2024 to 2031[1].

What are the main drivers of the zolpidem tartrate market?

The main drivers include the increasing prevalence of insomnia, an aging population, advances in pharmaceutical formulations, and growing healthcare infrastructure and spending[1][3][5].

How does the cost of zolpidem tartrate compare to other sleep aids?

Zolpidem tartrate is generally more cost-effective compared to other sleep aids like zaleplon and eszopiclone, with a cost of about $3 per tablet without insurance[4].

What impact did the COVID-19 pandemic have on the zolpidem tartrate market?

The COVID-19 pandemic led to an increase in demand for sleep aids, including zolpidem tartrate, due to increased stress, anxiety, and disrupted sleep patterns[3].

Who are the major players in the zolpidem tartrate market?

Major manufacturers include Sanofi, Merit Pharmaceutical, Par Pharmaceutical, Teva Pharmaceuticals USA, Inc., and Astellas Pharma US, Inc.[3].

What are the potential challenges facing the zolpidem tartrate market?

Challenges include regulatory measures, concerns over dependency, and potential side effects, as well as competition from other sleep aids and generic alternatives[5].

Sources

  1. Market Research Intellect: Zolpidem Tartrate Market Size, Share | Industry Research Report 2031
  2. Market Research Intellect: Global Zolpidem Tartrate API Market Size, Scope And Forecast Report
  3. Growth Market Reports: Zolpidem Tartrate Market Size, Share & Trends Growth [2031]
  4. SingleCare: How much is zolpidem tartrate (Ambien) without insurance?
  5. Data Horizzon Research: Zolpidem Tartrate Tablets Market Size, Share, Growth, Statistics ...

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.